NASDAQ:IBIO

iBio Q1 2026 Earnings Results & Report

iBio logo
$0.75 +0.04 (+5.86%)
Closing price 04:00 PM Eastern
Extended Trading
$0.76 +0.01 (+1.72%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

iBio missed analyst earnings expectations in its Q1 2026 results, released November 12, 2025. The company reported EPS of -$0.11 versus the -$0.07 consensus estimate, while revenue was $100 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call
4:00 PM ET

iBio EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.07
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 6 quarters

iBio Revenue Results

Actual Revenue
$100 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

iBio Q1 2026 Earnings FAQ

iBio (NASDAQ:IBIO) reported earnings of -$0.11 per share for Q1 2026, missing the consensus estimate of -$0.07. The report was announced on Wednesday, November 12, 2025.

iBio reported revenue of $100 thousand for Q1 2026.

iBio Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Brookline Capital Markets Boosts Earnings Estimates for iBio
See More iBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email.

About iBio

iBio (NASDAQ:IBIO) is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology.

The company’s current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development.

iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery. Its programs are in development, and the company’s research priorities may change as its pipeline advances.

View iBio Profile